Description: Nxera Pharma Co., Ltd. develops and sells biopharmaceutical products in Japan, Switzerland, the United States, Bermuda, and the United Kingdom. Its product portfolio products include Ultibro/Breezhaler and Seebri/Breezhaler for the treatment of chronic obstructive pulmonary disease; Enerzair and Breezhaler for the treatment of asthma; ORAVI, a novel formulation for the treatment of oropharyngeal candidiasis; and PIVLAZ for the treatment of cerebral vasospasm indications. The company's development products pipeline consists of HTL0039732 for immuno-oncology indications; HTL0048149 for schizophrenia disorders; Daridorexant for the treatment of insomnia; HTL0016878 for schizophrenia and other neuropsychiatric disorders; PF-07081532 for Type 2 diabetes mellitus and obesity; PF-07054894 for inflammatory bowel disease; PF-07258669 for anorexia; PF-06954522 for metabolic diseases; NBI-1117569 for neurology diseases; and NBI-1117570 for central nervous system (CNS) disorders. It is also involved in the development of GPR35 agonist, for inflammatory bowel disease/GI disorders, which is in preclinical stage; and other discovery and preclinical stage drugs. Nxera Pharma Co., Ltd. has a strategic collaboration with AbbVie, Biohaven, Genentech Inc., GSK, Pfizer Inc., Neurocrine Biosciences Inc., Novartis International AG, and Verily; and strategic research and development partnership with PrecisionLife to auto-immune disorders with the potential to identify new drug targets for the treatment of chronic conditions. Nxera Pharma Co., Ltd. was incorporated in 1990 and is headquartered in Tokyo, Japan.
Home Page: www.nxera.life
PMO Hanzomon
Tokyo,
102-0083
Japan
Phone:
81 3 5210 3290
Officers
| Name | Title |
|---|---|
| Dr. Shinichi Tamura | Founder & Chairman of the Board |
| Mr. Christopher Cargill | Representative Executive Officer, President, CEO & Director |
| Mr. Hironoshin Nomura | Executive Officer, Executive VP & CFO |
| Mr. Toshihiro Maeda | Executive VP & COO |
| Mr. Kieran Johnson F.C.A. | Executive Officer, Executive VP & Chief Accounting Officer |
| Mr. Kazuhiko Yoshizumi | Executive Officer, Executive VP & Chief Compliance Officer |
| Mr. Shinichiro Nishishita | VP of Investor Relations & Head of Regulatory Disclosures |
| Stacey Southall | Associate Director & Head of Biophysics |
| Ms. Candelle Chong | Executive Officer, Executive VP, CEO Office & Chief of Staff |
| Mr. Patrick Branch | Head of Business Development for Japan and the APAC region |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.3781 |
| Price-to-Sales TTM: | 0.021 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 372 |